There are currently four Phelan-McDermid syndrome drug programs that are now in or approaching human trials simultaneously. In this month’s CSO Science Corner, Dr. Ralf Schmid shares how this is a deliberate strategy to maximize chances that at least one program reaches the families who need it.

CureSHANK’s 3rd annual Phelan-McDermid Syndrome Drug Development Symposium brought together researchers, clinicians, industry leaders, and families for two days of remarkable science, community, and hope. Read on for key takeaways and insights that will shape the future of PMS drug development.